Objective To study the correlation of polyphenol oxidase(PPO) activity and baicalin synthesis in callus of Scutellaria baicalensisi.Methods PPO Activity was determined by ultraviolet spectrophotometry and the content of baicalin was detected by HPLC.The effects of various substances(ascorbic acid,sodium chloride,benzoic acid,polyvinylpyrrolidone,and copper sulfate) on PPO activity and the content of baicalin were studied.Results There was no baicalin accumulation in the first 20 d of growth period, while PPO activity was expressed slowly during this period.From 20 d to 35 d,PPO activity increased significantly and the baicalin secondary synthesis was restrained.Conclusion The high-level expression of PPO activity do harm the baicalin secondary synthesis.These chemical substances,such as ascorbic acid, sodium chloride,and benzoic acid could inhibit the PPO activity and improve the content of baicalin;It is obvious for ascorbic acid(0.02%) to improve the content of baicalin with 17.6%(82.3 mg/g) compared with the control.However,polyvinylpyrrolidone and copper sulfate could increase the PPO activity and greatly inhibit the baicalin accumulation.

Objective To study the rule of callus culture and baicalin synthesis in Scutellaria baicalensis. Methods Callus was induced by plant cell culture technology and the content of baicalin was determind by HPLC. Results The optimal culture medium on the growth of callus and the synthesis of baicalin in S. baicalensis is: MS culture medium, 60 mmol/L (NH_4+∶NO_3-=1∶1), 0.5—1.5 mmol/L KH_2PO_4, 80 g/L sucrose, 0.3 mg/L IAA, 2 mg/L 6-BA, and 200 mg/L peptone. When it was cultured for 40 d, the total biomass reached 28.7 g/L and the content of baicalin was 167.4 mg/g, which was much higher than that of wild S. baicalensis. Conclusion The growth of S. baicalensis callus and the accumulation of baicalin are not underway simultaneously; the callus grows first and then its secondary metabolic products synthesize. It is obvious for sucrose to regulate the baicalin synthesis. When the concentration of sucrose is less than 3%, it could only promote the callus growth; when between 3% and 8%, it could greatly increase not only the callus growth but also the baicalin synthesis, when 8%, both of them arrive to the maximum content.

In recent years, it has been well known that non-small cell lung cancer (NSCLC) patients with muta-tions of epidermal growth factor receptor (EGFR) response better to EGFR-tyrosine kinase inhibitor treatment. Although DNA-based assays (e.g. DNA sequencing) are the most frequently used and a relatively reliable method to detect EGFR muta-tions, they are complex, time-consuming and relatively expensive for routine use in clinical laboratories, besides they require high quality tumor samples. In contrast, the immunohistochemistry (IHC) methods make up fully for the above shortcomings and can serve as screening tests for EGFR mutations. However, there are many factors that can inlfuence the results of IHC methods, such as different staining procedures, different antigen retrieval solutions and different sets of criteria, etc. hTus the IHC methods for detecting EGFR mutations have not been widely used in clinic and only in the research stage. hTis article re-views the use of IHC methods by different researchers and further discusses how to make the IHC methods work best for the detection of EGFR mutations.

Objective:To investigate the value of the combined ultrasound imaging radiomics model for predicting progression-free survival in endocrine therapy for prostate cancer.Methods:A total of 283 prostate cancer patients who received endocrine treatment at the Inner Mongolia Autonomous Region People′s Hospital and the First Hospital of Hohhot from July 2018 to January 2023 were retrospectively collected, of which 198 patients from the Inner Mongolia Autonomous Region People′s Hospital were randomly divided into the training set and the validation set according to the ratio of 7∶3, and 85 patients from the First Hospital of Hohhot served as an independent external test set. They were classified into a progression group and a non-progression group based on whether the patients progressed to desmoplasia-resistant prostate cancer 18 months after the start of endocrine treatment.Based on the two-dimensional ultrasound images, the imaging radiomics features were extracted and the imaging radiomics score (Rad-score) were constructed, the immunopathology and other clinical data were analysed, and three prediction models were constructed using logistic regression: the clinical model, the ultrasonography model, and the ultrasonography-clinical combined model, respectively. The predictive efficacy and clinical utility of the models were assessed by the ROC curves and clinical decision curves.Results:Five ultrasonographic features were included in the ultrasound model; the prostate-specific antigen nadir, the neutrophil-to-lymphocyte ratio before treatment, and the expression level of tumour proliferating cell nuclear antigen 67 (Ki-67) were incorporated into the clinical model; and the Rad score computed from the output of the ultrasound model for the screening features, together with the prostate-specific antigen nadir (PSA nadir), the neutrophil to lymphocyte ratio (NLR) before treatment, and the expression level of Ki-67 were used to construct the ultrasound-clinical joint model. The joint model achieved the highest predictive performance in both the training and validation sets of the three groups of models, with the area under the curve of 0.85 and 0.84, and the clinical decision curve showed good clinical benefit.Conclusions:The combined ultrasound-clinical model constructed in this study based on two-dimensional ultrasound images of prostate cancer before endocrine therapy can predict progression-free survival of endocrine therapy for prostate cancer more accurately.

Targeted therapy is one of the major treatment modalities in advanced non-small cell lung cancer (NSCLC) with sensitive driver gene mutations. BRAF is considered a promising oncogenic driver in NSCLC after the discovery of epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion and ROS1 rearrangement. BRAF V600E mutation accounts for more than half of BRAF mutations, which is a potential therapeutic target for advanced NSCLC. This review aims to summarize the advancements of BRAF gene mutation and targeted therapy for BRAF mutation in NSCLC.
.
Carcinoma, Non-Small-Cell Lung ; drug therapy ; enzymology ; genetics ; pathology ; Drug Resistance, Neoplasm ; genetics ; Humans ; Lung Neoplasms ; drug therapy ; enzymology ; genetics ; pathology ; Molecular Targeted Therapy ; methods ; Mutation ; Proto-Oncogene Proteins B-raf ; genetics

BRAF gene mutation is found in about 2%-4% of the patients with non-small cell lung cancer (NSCLC). This type of NSCLC is characterized by high malignancy, low efficacy of chemotherapy and poor prognosis. Although the combination treatment of BRAF inhibitor and MEK inhibitor has achieved remarkable results in advanced NSCLC patients with BRAF V600E mutation, which has been written into the National Comprehensive Cancer Network (NCCN) guidelines, severe side effects of the combination therapy are frequently observed. There isn't effective treatment strategy after drug resistance, and targeted therapy for non-V600E mutation patients is still lacking. In this paper, we summarized the researches on expression of immune markers in NSCLC patients with mutant BRAF and analyzed the studies on efficacy of immune checkpoint inhibitor (ICI), so as to provide more options for prolonging survival of the patients.
.

Objective To investigate the efficacy of Zorifertinib in first-line treatment of patients with untreated epidermal growth factor receptor(EGFR)mutation in non-small-cell lung cancer(NSCLC)with central nervous system(CNS)metastases.Methods Two patients received Zorifertinib as first-line treatment.The response of tumor treatment was evaluated by response evaluation criteria in solid tumors version 1.1(RECEST v1.1)and RANO criteria for brain metastases(RANO-BM).Results Case 1 had EGFR exon 19del mutation and multiple brain metastases at baseline.After 51.4 months of treatment with Zorifertinib,case 1 still maintained partial response(PR)in lung lesions and complete response(CR)in intracranial lesions.Case 2 had EGFR exon 19del mutation and a single brain metastasis at baseline.Case 2 achieved PR in lung lesions and CR in intracranial lesions during the treatment with Zorifertinib.After 13.7 months,lung disease progression(PD)and new single brain metastases occurred.The comprehensive evaluation was PD.Case 1 had three-grade treatment-related adverse events(TRAEs),including dry skin,and other TRAEs were rash,abnormal liver function and diarrhea.The TRAEs were generally controllable.Conclusion Zorifertinib has a good effect on controlling intracranial and extracranial lesions in patients with EGFR-mutated NSCLC with CNS metastases.The efficacy of Zorifertinib is consistent with the EVEREST study.Zorifertinib can be one of the first-line initial treatment options.

Background and objective It has been proven that epidermal growth factor receptor (EGFR) mutation is the most important predictive factor for determining the effect of EGFR tyrosine kinase inhibitors (TKIs) applied to non-small cell lung cancer (NSCLC) patients. hTe patients with EGFR mutations response better to TKIs. To detect EGFR muta-tion has been particularly essential to select ifrst-line treatment for lung cancer patients. To research and analyze the sensitivity and speciifcity of immunohistochemistry (IHC) using mutation speciifc antibodies in detecting EGFR mutations compared with DNA sequencing, and further evaluate the accuracy and clinical application value of IHC. Methods All required articles in Pubmed database were searched. hTe deadline of retrieval was March 26, 2013. hTen further screening the articles based on the inclusion and exclusion criteria. Meta analysis of diagnostic test was applied to analyze the sensitivity and speciifcity of IHC compared with DNA sequencing for the detection of EGFR mutations. Results Ten articles were included in the meta analysis, there were 1,679 samples in L858R group and 1,041 samples in E746-A750del group. hTe DOR were 225.17 (95%CI:55.67-910.69) and 267.16 (95%CI:132.45-538.88) respectively;the AUC of SROC were 0.948,4 (SEAUC=0.014,4) and 0.981,3 (SEAUC=0.009,9) respectively;the Q values were 0.888,3 (SEQ*=0.019,2) and 0.939,7 (SEQ*=0.019,1) respectively. Conclusion hTe speciifcity and sensitivity of IHC method using these two mutation-speciifc antibodies were relatively high. As a screening method for EGFR mutations, the IHC with mutation speciifc antibodies is of clinical value.

Background and objective Carbonic anhydrase IX (CAIX) is a transmembrane protein involved in the metabolism of tumor cells. CAIX is expressed in only a few normal tissues but is overexpressed in various tumor types. Te aim of this study is to detect the serum CAIX level of patients with lung cancer, evaluate the significance of CAIX detection in the diagnosis of lung cancer, and analyze the serum CAIX level among diferent pathological types and TNM stages of lung can-cer. Methods Forty-seven patients with lung cancer and 31 healthy subjects were selected to participate in this study. Serum CAIX level was examined through enzyme-linked immunosorbent assay (ELISA). Te subjects were grouped according to histological type and TNM staging, and serum CAIX level was compared among the groups. With pathological diagnosis as the gold standard, receiver operating characteristic curve of the serum CAIX level was established for the diagnosis of lung cancer. Results Te CAIX serum level was significantly higher in patients with lung cancer than that in the healthy group (P<0.001). Te serum CAIX level in patients with squamous cell carcinoma and small cell carcinoma was also significantly higher than that in patients with adenocarcinoma. No statistically significant diferences were observed in the serum CAIX level between I+II and III+IV staging. Te AUC of serum CAIX level was 0.961. At a threshold level of 115.115 pg/mL, sensitivity and specificity were 95.7% and 90.3%, respectively. Conclusion Detection of the serum CAIX level through ELISA exhibits high sensitivity and specificity and is important for the diagnosis of lung cancer.

Background and objective Patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR) respond well to EGFR-tyrosine kinase inhibitor therapy. Immunohistochemistry (IHC) is a simple and widely used technique in clinical pathology laboratories. IHC also features cost effectiveness and rapid detection ofEGFR mutations compared with molecular methods. hTis study aims to determine the accuracy of IHC forEGFR mutation detection in NSCLC.Methods Specimens (obtained from surgery or biopsy) from 97 NSCLC cases were stained through IHC with mutation-specific antibodies. The clinicopathological features of patients with positive immunostaining results were analyzed. Positive specimens were subjected to liquid chip technology to detect the actual EGFR status. Forty NSCLC specimens obtained from surgery and conifrmed to haveEGFR mutations through liquid chip technology were collect-ed. These specimens were then subjected to IHC analyses with mutation-speciifc antibodies. The sensitivity of IHC in detect-ingEGFR mutations was calculated.Results Seventeen of the 97 NSCLC specimens were stained positive, and positive results were mostly observed in females, patients with adenocarcinoma, and non-smokers. About 76.9% of specimens with positive IHC results harbored mutations. The sensitivity of IHC was 40% among the 40 cases identiifed as containingEGFR mutations through liquid chip technology.Conclusion The strong positive immunostaining result is accurate, but the sensitivity of the method may not be optimal and signiifcantly varies in different studies. The widespread application of IHC in clinics must be further investigated.